Regimens of one IL-21 dose per day (e.g. 16 SC injections given between days 3–20 following B16 inoculation) were simulated under different dose intensities: A dose-dependent increase in the response, reflected by lowered tumor masses, was predicted for very low (<5 μg) or very high (>50 μg) levels (Fig. 5A). The gene discussed is IL21; the disease is neoplasm.